This property candidates irisin as a potential therapeutic target in metabolic diseases, including metabolic syndrome, T2DM, and nonalcoholic fatty liver disease (NAFLD), in which IR plays a major pathogenic role [143]. Here, FNDC5 is linked to metabolic syndrome.